Recently, Jiangsu Aiweide Biotechnology Co., Ltd. announced the completion of a new round of financing. This round of financing was led by the Nanjing Jiangbei New Area New Quality Research and Production Venture Capital Fund, followed by institutional and industrial capital such as the Nanjing Zijin Biomedical Industry Investment Fund, the Nanjing University Science and Technology Achievement Transformation Angel Fund, the Nanjing Xingong Biomedical Concept Verification Venture Capital Fund, Shanghai Bangmei Incubation Enterprise Management Partnership, and Shanghai Wanfeng New Material Technology Co., Ltd. The funds will focus on building standardized in vitro models for multi-organ chips, intelligent equipment research and development, AI image analysis system iteration, and construction of marketing systems and order delivery capabilities to accelerate the company from technical verification to large-scale application and commercialization.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.